Show Notes
What happens when multiple sclerosis symptoms mask a different condition?
In this episode of Mayo Clinic’s Tomorrow’s Cure, hosted by Lindsey Seavert, we explore myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), an autoimmune condition often mistaken for multiple sclerosis (MS). Mayo Clinic neurologist Eoin Flanagan, M.D., B.Ch., and pediatric neurologist Brenda Banwell, M.D., discuss how MOG antibodies define a distinct disease, why early recognition and aggressive treatment of acute attacks are critical, and how MOGAD can present with severe optic neuritis, spinal cord inflammation, and brain involvement such as confusion or seizures. They explain the internationally accepted 2023 diagnostic criteria, which integrate clinical syndromes, MRI findings, and antibody testing while accounting for false positives and changing antibody levels over time. The conversation highlights “vanishing” MRI lesions in MOGAD, patient-driven research, emerging relapse-prevention trials, and therapeutic promise in targeting pathways such as IL-6.
How to listen and stay connected:
Subscribe to Tomorrow’s Cure on your favorite podcast app and follow the show so you never miss an episode.
Get the latest health information from Mayo Clinic’s experts—subscribe to Mayo Clinic’s newsletter for free today: https://mayocl.in/3EcNPNc
Connect with Mayo Clinic:
Like Mayo Clinic on Facebook: https://www.facebook.com/mayoclinic/
Follow Mayo Clinic on Instagram: https://www.instagram.com/mayoclinic/
Follow Mayo Clinic on X (formerly Twitter): https://x.com/MayoClinic
Follow Mayo Clinic on Threads: https://www.threads.net/@mayoclinic
More from Tomorrow's Cure
How could Mayo Clinic’s Global AI Platform transform personalized care?
What if transplant patients could one day live free from lifelong anti-rejection drugs?
What if repairing damaged cartilage could be done in a single procedure? Using your own cells and the healing signals they need to recover?
What if the milk you are drinking could help fight cancer? In this episode of Tomorrow's Cure, we explore cholangiocarcinoma and a surprising new approach to targeting it using milk‑derived nanoparticles and precision aptamer‑based delivery. Host Lindsey Seavert is joined by surgical oncologist Dr. Rory Smoot and long‑term survivor and advocate Melinda Bachini to unpack why this cancer is so challenging, what symptoms and treatment paths patients typically face, and how emerging gene‑delivery platforms and AI‑driven discovery are opening new possibilities when standard therapies fall short. Through Melinda’s 16‑year survivorship story and Dr. Smoot’s lab work that literally starts with skim milk from the Mayo Clinic cafeteria, listeners hear how “chemical antibodies” called aptamers can act as molecular keys to deliver therapy directly to cholangiocarcinoma cells, and how computational tools are accelerating the search for new targets. Together, they discuss the emotional and practical realities of living at the edge of what medicine can do today, the expanding landscape of clinical trials, and why innovation in this rare cancer may ripple out to colon, lung and other hard‑to‑treat tumors.
What if surgeons could make tumors, blood vessels, and other critical structures visible during surgery? In this episode of Tomorrow’s Cure, host Lindsey Seavert talks with Dr. Stephanie Polites of Mayo Clinic and Dr. Timothy Lautz of Lurie Children’s Hospital about fluorescence-guided surgery and its growing role in pediatric oncology, surgical oncology, and cancer treatment. By using specialized dyes and advanced imaging, surgeons can better identify tumors, protect healthy tissue, and perform more precise, minimally invasive procedures.The conversation explores the latest innovations in pediatric cancer surgery, including tumor-targeted fluorescent imaging agents, clinical trials, and new approaches that may help surgeons remove cancer more completely while preserving healthy anatomy.